Compounds > 5-dimethylaminophenylazoindazole
Page last updated: 2024-11-07

5-dimethylaminophenylazoindazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-dimethylaminophenylazoindazole: noncarcinogenic bacterial mutagen DAB analog; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107790
MeSH IDM0113106

Synonyms (10)

Synonym
17309-86-3
5-((p-(dimethylamino)phenyl)azo)-1h-indazole
ccris 6184
5-dimethylaminophenylazoindazole
5-dimethylaminophenylazoindole
1h-indazole, 5-((p-(dimethylamino)phenyl)azo)-
5-(4-dimethylaminophenylazo)-1h-indazole
4-(1h-indazol-5-yldiazenyl)-n,n-dimethylaniline
5-(p-dimethylamino-phenylazo)indazole
DTXSID901030938

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" As part of these studies we have determined (a) target organ distribution after oral dosing to rats and (b) covalent binding of 14C-labelled compound to DNA."( DNA-binding studies with 6BT and 5I: implications for DNA-binding/carcinogenicity and DNA-binding/mutagenicity correlations.
Ashby, J; Combes, RD; Dashwood, RH, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methyldimethylaminoazobenzene
Methyldimethylaminoazobenzene: A very potent liver carcinogen.. 3-methyl-4'-dimethylaminoazobenzene : A member of the class of azobenzenes that is azobenzene in which one of the phenyl groups is substituted at position 3 by a methyl group, while the other is substituted at position 4 by a dimethylamino group. It is a potent liver carcinogen.		1.9610
p-dimethylaminoazobenzene
p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound may reasonably be anticipated to be a carcinogen. (Merck, 11th ed)		3.0650azobenzenes
thiazoles
[no description available]		3.06501,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
n,n-dimethyl-4-(6-benzothiazolylazo)aniline
N,N-dimethyl-4-(6-benzothiazolylazo)aniline: do not confuse with 5-isomer (RN: 18463-90-6) also given this name in 9CI; structure		3.0650
4-n-pyrrolidinylazobenzene
4-N-pyrrolidinylazobenzene: structure given in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials